Development of a Self-Assembled Nanoparticle Formulation of Orlistat, Nano-ORL, with Increased Cytotoxicity against Human Tumor Cell Lines
Fatty acid synthase (FASN), the enzyme that catalyzes de novo synthesis of fatty acids, is expressed in many cancer types. Its potential as a therapeutic target is well recognized, but inhibitors of FASN have not yet been approved for cancer therapy. Orlistat (ORL), an FDA-approved lipase inhibitor,...
Gespeichert in:
Veröffentlicht in: | Molecular pharmaceutics 2016-03, Vol.13 (3), p.720-728 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 728 |
---|---|
container_issue | 3 |
container_start_page | 720 |
container_title | Molecular pharmaceutics |
container_volume | 13 |
creator | Hill, Tanner K Davis, Amanda L Wheeler, Frances B Kelkar, Sneha S Freund, Erica C Lowther, W. Todd Kridel, Steven J Mohs, Aaron M |
description | Fatty acid synthase (FASN), the enzyme that catalyzes de novo synthesis of fatty acids, is expressed in many cancer types. Its potential as a therapeutic target is well recognized, but inhibitors of FASN have not yet been approved for cancer therapy. Orlistat (ORL), an FDA-approved lipase inhibitor, is also an effective inhibitor of FASN. However, ORL is extremely hydrophobic and has low systemic uptake after oral administration. Thus, new strategies are required to formulate ORL for cancer treatment as a FASN inhibitor. Here, we report the development of a nanoparticle (NP) formulation of ORL using amphiphilic bioconjugates that are derived from hyaluronic acid (HA), termed Nano-ORL. The NPs were loaded with up to 20 wt % weight of ORL at greater than 95% efficiency. The direct inhibition of the human recombinant thioesterase domain of FASN by ORL extracted from Nano-ORL was similar to that of stock ORL. Nano-ORL demonstrated a similar ability to inhibit cellular FASN activity when compared to free ORL, as demonstrated by analysis of 14C-acetate incorporation into lipids. Nano-ORL treatment also disrupted mitochondrial function similarly to ORL by reducing adenosine triphosphate turnover in MDA-MB-231 and LNCaP cells. Nano-ORL demonstrated increased potency compared to ORL toward prostate and breast cancer cells. Nano-ORL decreased viability of human prostate and breast cancer cell lines to 55 and 57%, respectively, while free ORL decreased viability to 71 and 79% in the same cell lines. Moreover, Nano-ORL retained cytotoxic activity after a 24 h preincubation in aqueous conditions. Preincubation of ORL dramatically reduced the efficacy of ORL as indicated by high cell viability (>85%) in both breast and prostate cell lines. These data demonstrate that NP formulation of ORL using HA-derived polymers retains similar levels of FASN, lipid synthesis, and ATP turnover inhibition while significantly improving the cytotoxic activity against cancer cell lines. |
doi_str_mv | 10.1021/acs.molpharmaceut.5b00447 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4783219</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1771450284</sourcerecordid><originalsourceid>FETCH-LOGICAL-a469t-abf2256077337bb26a70a71f441f03dcd65c1709c0318defb9dc5117f5984d83</originalsourceid><addsrcrecordid>eNqNkd1u0zAYhiMEYmNwC8iccbAU23Hi5ARpKoxNqqgEPbe-OM7qyT_BdjZ6C1w1Li0VO-PIlvy8j_35LYp3BC8IpuQDyLiw3kxbCBakmtOi7jFmjD8rzknNqrKtOvr8tG_ZWfEqxnuMKatp9bI4o01LGWH0vPj1ST0o4yerXEJ-RIC-KzOWVzEq2xs1oK_g_AQhaWkUuvbBzgaS9m4Pr4PRMUG6_EOV62-rS_So0xbdOhkUxBxf7pJP_qeWOu0Q3IF2MaGb2YJDm9n6gJbKGLTSTsXXxYsRTFRvjutFsbn-vFnelKv1l9vl1aoE1nSphH6ktG4w51XF-542wDFwMjJGRlwNcmhqSTjuJK5IO6ix7wZZE8LHumvZ0FYXxceDdpp7qwaZBw9gxBS0hbATHrR4euL0Vtz5B8F4W1HSZcH7oyD4H7OKSVgdZR4DnPJzFIRzwmpMW5bR7oDK4GMMajxdQ7DYVylyleJJleJYZc6-_fedp-Tf7jJQH4C9497PweVf-w_xb4hdtcA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1771450284</pqid></control><display><type>article</type><title>Development of a Self-Assembled Nanoparticle Formulation of Orlistat, Nano-ORL, with Increased Cytotoxicity against Human Tumor Cell Lines</title><source>MEDLINE</source><source>ACS Publications</source><creator>Hill, Tanner K ; Davis, Amanda L ; Wheeler, Frances B ; Kelkar, Sneha S ; Freund, Erica C ; Lowther, W. Todd ; Kridel, Steven J ; Mohs, Aaron M</creator><creatorcontrib>Hill, Tanner K ; Davis, Amanda L ; Wheeler, Frances B ; Kelkar, Sneha S ; Freund, Erica C ; Lowther, W. Todd ; Kridel, Steven J ; Mohs, Aaron M</creatorcontrib><description>Fatty acid synthase (FASN), the enzyme that catalyzes de novo synthesis of fatty acids, is expressed in many cancer types. Its potential as a therapeutic target is well recognized, but inhibitors of FASN have not yet been approved for cancer therapy. Orlistat (ORL), an FDA-approved lipase inhibitor, is also an effective inhibitor of FASN. However, ORL is extremely hydrophobic and has low systemic uptake after oral administration. Thus, new strategies are required to formulate ORL for cancer treatment as a FASN inhibitor. Here, we report the development of a nanoparticle (NP) formulation of ORL using amphiphilic bioconjugates that are derived from hyaluronic acid (HA), termed Nano-ORL. The NPs were loaded with up to 20 wt % weight of ORL at greater than 95% efficiency. The direct inhibition of the human recombinant thioesterase domain of FASN by ORL extracted from Nano-ORL was similar to that of stock ORL. Nano-ORL demonstrated a similar ability to inhibit cellular FASN activity when compared to free ORL, as demonstrated by analysis of 14C-acetate incorporation into lipids. Nano-ORL treatment also disrupted mitochondrial function similarly to ORL by reducing adenosine triphosphate turnover in MDA-MB-231 and LNCaP cells. Nano-ORL demonstrated increased potency compared to ORL toward prostate and breast cancer cells. Nano-ORL decreased viability of human prostate and breast cancer cell lines to 55 and 57%, respectively, while free ORL decreased viability to 71 and 79% in the same cell lines. Moreover, Nano-ORL retained cytotoxic activity after a 24 h preincubation in aqueous conditions. Preincubation of ORL dramatically reduced the efficacy of ORL as indicated by high cell viability (>85%) in both breast and prostate cell lines. These data demonstrate that NP formulation of ORL using HA-derived polymers retains similar levels of FASN, lipid synthesis, and ATP turnover inhibition while significantly improving the cytotoxic activity against cancer cell lines.</description><identifier>ISSN: 1543-8384</identifier><identifier>EISSN: 1543-8392</identifier><identifier>DOI: 10.1021/acs.molpharmaceut.5b00447</identifier><identifier>PMID: 26824142</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>Apoptosis - drug effects ; Breast Neoplasms - drug therapy ; Breast Neoplasms - enzymology ; Breast Neoplasms - pathology ; Cell Proliferation - drug effects ; Drug Compounding ; Enzyme Inhibitors - administration & dosage ; Enzyme Inhibitors - pharmacology ; Fatty Acid Synthases - antagonists & inhibitors ; Fatty Acid Synthesis Inhibitors - administration & dosage ; Fatty Acid Synthesis Inhibitors - pharmacology ; Female ; Humans ; Lactones - administration & dosage ; Lactones - pharmacology ; Male ; Mitochondria - drug effects ; Mitochondria - enzymology ; Nanoparticles - administration & dosage ; Nanoparticles - chemistry ; Orlistat ; Prostatic Neoplasms - drug therapy ; Prostatic Neoplasms - enzymology ; Prostatic Neoplasms - pathology ; Tumor Cells, Cultured</subject><ispartof>Molecular pharmaceutics, 2016-03, Vol.13 (3), p.720-728</ispartof><rights>Copyright © 2016 American Chemical Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a469t-abf2256077337bb26a70a71f441f03dcd65c1709c0318defb9dc5117f5984d83</citedby><cites>FETCH-LOGICAL-a469t-abf2256077337bb26a70a71f441f03dcd65c1709c0318defb9dc5117f5984d83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.5b00447$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/acs.molpharmaceut.5b00447$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>230,314,776,780,881,2751,27055,27903,27904,56716,56766</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26824142$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hill, Tanner K</creatorcontrib><creatorcontrib>Davis, Amanda L</creatorcontrib><creatorcontrib>Wheeler, Frances B</creatorcontrib><creatorcontrib>Kelkar, Sneha S</creatorcontrib><creatorcontrib>Freund, Erica C</creatorcontrib><creatorcontrib>Lowther, W. Todd</creatorcontrib><creatorcontrib>Kridel, Steven J</creatorcontrib><creatorcontrib>Mohs, Aaron M</creatorcontrib><title>Development of a Self-Assembled Nanoparticle Formulation of Orlistat, Nano-ORL, with Increased Cytotoxicity against Human Tumor Cell Lines</title><title>Molecular pharmaceutics</title><addtitle>Mol. Pharmaceutics</addtitle><description>Fatty acid synthase (FASN), the enzyme that catalyzes de novo synthesis of fatty acids, is expressed in many cancer types. Its potential as a therapeutic target is well recognized, but inhibitors of FASN have not yet been approved for cancer therapy. Orlistat (ORL), an FDA-approved lipase inhibitor, is also an effective inhibitor of FASN. However, ORL is extremely hydrophobic and has low systemic uptake after oral administration. Thus, new strategies are required to formulate ORL for cancer treatment as a FASN inhibitor. Here, we report the development of a nanoparticle (NP) formulation of ORL using amphiphilic bioconjugates that are derived from hyaluronic acid (HA), termed Nano-ORL. The NPs were loaded with up to 20 wt % weight of ORL at greater than 95% efficiency. The direct inhibition of the human recombinant thioesterase domain of FASN by ORL extracted from Nano-ORL was similar to that of stock ORL. Nano-ORL demonstrated a similar ability to inhibit cellular FASN activity when compared to free ORL, as demonstrated by analysis of 14C-acetate incorporation into lipids. Nano-ORL treatment also disrupted mitochondrial function similarly to ORL by reducing adenosine triphosphate turnover in MDA-MB-231 and LNCaP cells. Nano-ORL demonstrated increased potency compared to ORL toward prostate and breast cancer cells. Nano-ORL decreased viability of human prostate and breast cancer cell lines to 55 and 57%, respectively, while free ORL decreased viability to 71 and 79% in the same cell lines. Moreover, Nano-ORL retained cytotoxic activity after a 24 h preincubation in aqueous conditions. Preincubation of ORL dramatically reduced the efficacy of ORL as indicated by high cell viability (>85%) in both breast and prostate cell lines. These data demonstrate that NP formulation of ORL using HA-derived polymers retains similar levels of FASN, lipid synthesis, and ATP turnover inhibition while significantly improving the cytotoxic activity against cancer cell lines.</description><subject>Apoptosis - drug effects</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - enzymology</subject><subject>Breast Neoplasms - pathology</subject><subject>Cell Proliferation - drug effects</subject><subject>Drug Compounding</subject><subject>Enzyme Inhibitors - administration & dosage</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Fatty Acid Synthases - antagonists & inhibitors</subject><subject>Fatty Acid Synthesis Inhibitors - administration & dosage</subject><subject>Fatty Acid Synthesis Inhibitors - pharmacology</subject><subject>Female</subject><subject>Humans</subject><subject>Lactones - administration & dosage</subject><subject>Lactones - pharmacology</subject><subject>Male</subject><subject>Mitochondria - drug effects</subject><subject>Mitochondria - enzymology</subject><subject>Nanoparticles - administration & dosage</subject><subject>Nanoparticles - chemistry</subject><subject>Orlistat</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>Prostatic Neoplasms - enzymology</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Tumor Cells, Cultured</subject><issn>1543-8384</issn><issn>1543-8392</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkd1u0zAYhiMEYmNwC8iccbAU23Hi5ARpKoxNqqgEPbe-OM7qyT_BdjZ6C1w1Li0VO-PIlvy8j_35LYp3BC8IpuQDyLiw3kxbCBakmtOi7jFmjD8rzknNqrKtOvr8tG_ZWfEqxnuMKatp9bI4o01LGWH0vPj1ST0o4yerXEJ-RIC-KzOWVzEq2xs1oK_g_AQhaWkUuvbBzgaS9m4Pr4PRMUG6_EOV62-rS_So0xbdOhkUxBxf7pJP_qeWOu0Q3IF2MaGb2YJDm9n6gJbKGLTSTsXXxYsRTFRvjutFsbn-vFnelKv1l9vl1aoE1nSphH6ktG4w51XF-542wDFwMjJGRlwNcmhqSTjuJK5IO6ix7wZZE8LHumvZ0FYXxceDdpp7qwaZBw9gxBS0hbATHrR4euL0Vtz5B8F4W1HSZcH7oyD4H7OKSVgdZR4DnPJzFIRzwmpMW5bR7oDK4GMMajxdQ7DYVylyleJJleJYZc6-_fedp-Tf7jJQH4C9497PweVf-w_xb4hdtcA</recordid><startdate>20160307</startdate><enddate>20160307</enddate><creator>Hill, Tanner K</creator><creator>Davis, Amanda L</creator><creator>Wheeler, Frances B</creator><creator>Kelkar, Sneha S</creator><creator>Freund, Erica C</creator><creator>Lowther, W. Todd</creator><creator>Kridel, Steven J</creator><creator>Mohs, Aaron M</creator><general>American Chemical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160307</creationdate><title>Development of a Self-Assembled Nanoparticle Formulation of Orlistat, Nano-ORL, with Increased Cytotoxicity against Human Tumor Cell Lines</title><author>Hill, Tanner K ; Davis, Amanda L ; Wheeler, Frances B ; Kelkar, Sneha S ; Freund, Erica C ; Lowther, W. Todd ; Kridel, Steven J ; Mohs, Aaron M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a469t-abf2256077337bb26a70a71f441f03dcd65c1709c0318defb9dc5117f5984d83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Apoptosis - drug effects</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - enzymology</topic><topic>Breast Neoplasms - pathology</topic><topic>Cell Proliferation - drug effects</topic><topic>Drug Compounding</topic><topic>Enzyme Inhibitors - administration & dosage</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Fatty Acid Synthases - antagonists & inhibitors</topic><topic>Fatty Acid Synthesis Inhibitors - administration & dosage</topic><topic>Fatty Acid Synthesis Inhibitors - pharmacology</topic><topic>Female</topic><topic>Humans</topic><topic>Lactones - administration & dosage</topic><topic>Lactones - pharmacology</topic><topic>Male</topic><topic>Mitochondria - drug effects</topic><topic>Mitochondria - enzymology</topic><topic>Nanoparticles - administration & dosage</topic><topic>Nanoparticles - chemistry</topic><topic>Orlistat</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>Prostatic Neoplasms - enzymology</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Tumor Cells, Cultured</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hill, Tanner K</creatorcontrib><creatorcontrib>Davis, Amanda L</creatorcontrib><creatorcontrib>Wheeler, Frances B</creatorcontrib><creatorcontrib>Kelkar, Sneha S</creatorcontrib><creatorcontrib>Freund, Erica C</creatorcontrib><creatorcontrib>Lowther, W. Todd</creatorcontrib><creatorcontrib>Kridel, Steven J</creatorcontrib><creatorcontrib>Mohs, Aaron M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Molecular pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hill, Tanner K</au><au>Davis, Amanda L</au><au>Wheeler, Frances B</au><au>Kelkar, Sneha S</au><au>Freund, Erica C</au><au>Lowther, W. Todd</au><au>Kridel, Steven J</au><au>Mohs, Aaron M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of a Self-Assembled Nanoparticle Formulation of Orlistat, Nano-ORL, with Increased Cytotoxicity against Human Tumor Cell Lines</atitle><jtitle>Molecular pharmaceutics</jtitle><addtitle>Mol. Pharmaceutics</addtitle><date>2016-03-07</date><risdate>2016</risdate><volume>13</volume><issue>3</issue><spage>720</spage><epage>728</epage><pages>720-728</pages><issn>1543-8384</issn><eissn>1543-8392</eissn><abstract>Fatty acid synthase (FASN), the enzyme that catalyzes de novo synthesis of fatty acids, is expressed in many cancer types. Its potential as a therapeutic target is well recognized, but inhibitors of FASN have not yet been approved for cancer therapy. Orlistat (ORL), an FDA-approved lipase inhibitor, is also an effective inhibitor of FASN. However, ORL is extremely hydrophobic and has low systemic uptake after oral administration. Thus, new strategies are required to formulate ORL for cancer treatment as a FASN inhibitor. Here, we report the development of a nanoparticle (NP) formulation of ORL using amphiphilic bioconjugates that are derived from hyaluronic acid (HA), termed Nano-ORL. The NPs were loaded with up to 20 wt % weight of ORL at greater than 95% efficiency. The direct inhibition of the human recombinant thioesterase domain of FASN by ORL extracted from Nano-ORL was similar to that of stock ORL. Nano-ORL demonstrated a similar ability to inhibit cellular FASN activity when compared to free ORL, as demonstrated by analysis of 14C-acetate incorporation into lipids. Nano-ORL treatment also disrupted mitochondrial function similarly to ORL by reducing adenosine triphosphate turnover in MDA-MB-231 and LNCaP cells. Nano-ORL demonstrated increased potency compared to ORL toward prostate and breast cancer cells. Nano-ORL decreased viability of human prostate and breast cancer cell lines to 55 and 57%, respectively, while free ORL decreased viability to 71 and 79% in the same cell lines. Moreover, Nano-ORL retained cytotoxic activity after a 24 h preincubation in aqueous conditions. Preincubation of ORL dramatically reduced the efficacy of ORL as indicated by high cell viability (>85%) in both breast and prostate cell lines. These data demonstrate that NP formulation of ORL using HA-derived polymers retains similar levels of FASN, lipid synthesis, and ATP turnover inhibition while significantly improving the cytotoxic activity against cancer cell lines.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>26824142</pmid><doi>10.1021/acs.molpharmaceut.5b00447</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1543-8384 |
ispartof | Molecular pharmaceutics, 2016-03, Vol.13 (3), p.720-728 |
issn | 1543-8384 1543-8392 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4783219 |
source | MEDLINE; ACS Publications |
subjects | Apoptosis - drug effects Breast Neoplasms - drug therapy Breast Neoplasms - enzymology Breast Neoplasms - pathology Cell Proliferation - drug effects Drug Compounding Enzyme Inhibitors - administration & dosage Enzyme Inhibitors - pharmacology Fatty Acid Synthases - antagonists & inhibitors Fatty Acid Synthesis Inhibitors - administration & dosage Fatty Acid Synthesis Inhibitors - pharmacology Female Humans Lactones - administration & dosage Lactones - pharmacology Male Mitochondria - drug effects Mitochondria - enzymology Nanoparticles - administration & dosage Nanoparticles - chemistry Orlistat Prostatic Neoplasms - drug therapy Prostatic Neoplasms - enzymology Prostatic Neoplasms - pathology Tumor Cells, Cultured |
title | Development of a Self-Assembled Nanoparticle Formulation of Orlistat, Nano-ORL, with Increased Cytotoxicity against Human Tumor Cell Lines |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T20%3A13%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20a%20Self-Assembled%20Nanoparticle%20Formulation%20of%20Orlistat,%20Nano-ORL,%20with%20Increased%20Cytotoxicity%20against%20Human%20Tumor%20Cell%20Lines&rft.jtitle=Molecular%20pharmaceutics&rft.au=Hill,%20Tanner%20K&rft.date=2016-03-07&rft.volume=13&rft.issue=3&rft.spage=720&rft.epage=728&rft.pages=720-728&rft.issn=1543-8384&rft.eissn=1543-8392&rft_id=info:doi/10.1021/acs.molpharmaceut.5b00447&rft_dat=%3Cproquest_pubme%3E1771450284%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1771450284&rft_id=info:pmid/26824142&rfr_iscdi=true |